ASP-8062
- Generic Name
- ASP-8062
Human Laboratory Study of ASP8062 for Alcohol Use Disorder
Phase 2
Completed
- Conditions
- Alcohol Use DisorderAlcohol Use Disorder (AUD)Alcohol Drinking
- Interventions
- Drug: Placebo
- First Posted Date
- 2021-10-27
- Last Posted Date
- 2024-12-03
- Lead Sponsor
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Target Recruit Count
- 60
- Registration Number
- NCT05096117
- Locations
- 🇺🇸
University of California Los Angeles, Los Angeles, California, United States
🇺🇸University of Colorado, Aurora, Colorado, United States
🇺🇸Brown University, Providence, Rhode Island, United States
A Study to Assess the Safety and Efficacy of ASP8062 as an Add-on Therapy to Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Phase 2
Withdrawn
- Conditions
- Opioid Use Disorder
- Interventions
- First Posted Date
- 2021-09-30
- Last Posted Date
- 2024-11-06
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Registration Number
- NCT05062577
A Study to Assess the Effect of a Single Dose of ASP8062 on the Multiple Dose Safety, Tolerability and Pharmacokinetics of Buprenorphine/Naloxone in Participants With Opioid Use Disorder
Phase 1
Completed
- Conditions
- Opioid Use Disorder
- Interventions
- First Posted Date
- 2020-06-25
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT04447287
- Locations
- 🇺🇸
Altasciences Clinical Kansas, Inc., Overland Park, Kansas, United States
A Study to Assess Potential Interaction Between ASP8062 and Alcohol in Healthy Adult Subjects
Phase 1
Completed
- Conditions
- Healthy Volunteers
- Interventions
- First Posted Date
- 2019-07-01
- Last Posted Date
- 2024-11-05
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 20
- Registration Number
- NCT04003402
- Locations
- 🇺🇸
Parexel International - EPCU Baltimore, Baltimore, Maryland, United States
Study to Evaluate the Safety and Tolerability of ASP8062 in Healthy Japanese Male and Female Subjects
- First Posted Date
- 2017-06-12
- Last Posted Date
- 2024-10-21
- Lead Sponsor
- Astellas Pharma Inc
- Target Recruit Count
- 36
- Registration Number
- NCT03183739
- Locations
- 🇯🇵
Site JP00001, Sumida, Tokyo, Japan
A Study to Assess the Analgesic Efficacy and Safety of ASP8062 in Subjects With Fibromyalgia
- First Posted Date
- 2017-03-28
- Last Posted Date
- 2024-11-21
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 183
- Registration Number
- NCT03092726
- Locations
- 🇺🇸
Chicago Research Center, Inc, Chicago, Illinois, United States
🇺🇸Lehigh Center for Clinical Research, Allentown, Pennsylvania, United States
🇺🇸PAB Clinical Research, Brandon, Florida, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath